Dowling & Yahnke’s GENEREX BIOTECHNOLOGY CORP GNBT Stock Holding History

Dowling & Yahnke’s Portfolio GNBT Stock Details GNBT Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2016 Q3	–	Sell	-21,000	Closed	–	–	272
2016 Q2	$0	Buy	+21,000	New	–	﹤0.01%	275

Dowling & Yahnke's GNBT Position: Q3 2016 in Review

Dowling & Yahnke sold out of GENEREX BIOTECHNOLOGY CORP (GNBT) in Q3 2016, closing a stake of 21,000 shares.

Dowling & Yahnke first reported a position in GNBT in Q2 2016 and held it in 1 quarter. The position peaked at $0 in Q2 2016. 0 funds tracked by Wall St. Rank hold GNBT as of Q3 2016.

Dowling & Yahnke reported no remaining GENEREX BIOTECHNOLOGY CORP position as of Q3 2016 after selling out during the quarter.
Dowling & Yahnke sold 21,000 GENEREX BIOTECHNOLOGY CORP shares in Q3 2016.
Dowling & Yahnke first reported a position in GENEREX BIOTECHNOLOGY CORP in Q2 2016 and held it in 1 quarter.
Dowling & Yahnke's GENEREX BIOTECHNOLOGY CORP position peaked at $0 in Q2 2016.
0 funds tracked by Wall St. Rank held GENEREX BIOTECHNOLOGY CORP as of Q3 2016.

Based on Dowling & Yahnke's 13F filing for Q3 2016, filed 20 Oct 2016.